02:14 , Aug 10, 2019 |  BioCentury  |  Product Development

Payers’ view of reimbursement when gene therapy isn’t enough

Spinal muscular atrophy is giving payers a new conundrum, and the indication is poised to become a testing ground with implications for many if not all gene therapies. The issue is whether, and how, payers...
21:32 , Jul 9, 2019 |  BC Extra  |  Financial News

July 9 Financial Quick Takes: ADC tops off megaround with $27M; plus Genmab, GNS, StemRIM and more

ADC closes expanded E round at $303M   ADC Therapeutics S.A. (Lausanne, Switzerland) raised an additional $27 million in its expanded series E round, which closed at $303 million. In June, the developer of antibody-drug...
00:47 , Feb 23, 2019 |  BioCentury  |  Tools & Techniques

Modeling now for precision later

GNS Healthcare Inc. is building a platform that aims to make value-based payment models unnecessary by giving companies a way to know which patients will respond before they even launch the drug. While drug companies...
23:44 , Jan 23, 2019 |  BC Extra  |  Company News

Management tracks: Cabaletta, Sage, MyoKardia

Autoimmune cell therapy company Cabaletta Bio Inc. (Radnor, Pa.) hired Anup Marda as CFO. He was VP and head of global corporate financial planning and analysis at Bristol-Myers Squibb Co. (NYSE:BMY). Marda succeeds interim CFO...
03:46 , Sep 29, 2018 |  BioCentury  |  Product Development

Deferred differentiation in migraine

The best hope for CGRP antagonists to differentiate themselves lies in data that aren’t yet available. In the meantime, the makers of the migraine therapies will likely have to trade discounts on their already reasonable...
20:38 , Sep 21, 2018 |  BioCentury  |  Politics, Policy & Law

Filling the rebate void

HHS’s proposal to eliminate drug rebates should have the intended consequence of increasing transparency into drug pricing in the short term. But the long view is that value-based pricing or alternative co-pay agreements will do...
03:01 , Sep 1, 2018 |  BioCentury  |  Politics, Policy & Law

Back to School: A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
06:14 , Aug 10, 2018 |  BC Week In Review  |  Company News

CVS earns less off rebates than the Street thought

CVS Health Corp. (NYSE:CVS) reported lower-than-expected contribution of retained rebates to its 2Q18 earnings and drew closer to completing its acquisition of Aetna Inc. (NYSE:AET) -- a move expected to cut its healthcare costs. CVS...
22:06 , Aug 9, 2018 |  BC Extra  |  Company News

CVS earns less off rebates than the Street thought

CVS Health Corp. (NYSE:CVS) reported lower-than-expected contribution of retained rebates to its 2Q18 earnings and drew closer to completing its acquisition of Aetna Inc. (NYSE:AET) -- a move expected to cut its healthcare costs. CVS...
23:06 , Jun 7, 2018 |  BC Extra  |  Company News

Management tracks: Alder, BIO

Neurology company Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) hired Robert Azelby as president and CEO, effective June 13. Azelby was EVP and chief commercial officer at Juno Therapeutics Inc., which Celgene Corp. (NASDAQ:CELG) acquired. The Biotechnology Innovation...